[ad_1]
It works through a nasopharyngeal swab, with a faster and less expensive procedure
To use the new test, the sample is taken from the patient with a nasopharyngeal swab: in case of infection, Afias detects the presence of the antigen and also highlights the viral load. The same instrumentation can also be used for serological research, measuring the amount of IgM and IgG antibodies present in the patient’s blood. In practice, the platform allows both tests to be performed: swab and serological test.
These tests differ from those of molecular biology because, although the medium used is always the nasopharyngeal swab, the antigen tests do not look for the genetic material of the virus, but rather detect the presence of the antigen and therefore of a possible infection through the investigation. virus specific proteins. The instrumentation used is faster and less expensive: it is the AFIAS Point of Care platform, distributed by Menarini Diagnostics in Italy and in other European countries, which can be used in decentralized operating contexts compared to the analysis laboratory, such as rooms emergency and airports.
There are currently two models available: AFIAS 1, which allows one test to be performed at a time, and AFIAS 6, which allows the examination of 6 samples simultaneously. With the same platform is
It is also possible to perform serological tests, detecting the presence and amount of IgM and IgG antibodies in a patient’s blood sample. With the use of AFIAS 6, for example, three patients can have simultaneously, in 12 minutes, the results of the serological and antigen test. “It is extremely important to provide reliable tests that allow large-scale detection and rapid detection of positive cases to contain the spread of COVID-19,” said Fabio Piazzalunga, global director of A. Menarini Diagnostics.
[ad_2]
